Review of Efficacy of Baricitinib in the Treatment of Alopecia Areata

April 2023 in “ International Journal of Research in Dermatology ”

Sultan Daghafak Alenazi, Mutaib A. Altamimi

baricitinib Janus kinase inhibitor JAK inhibitor alopecia areata autoimmune condition hair loss AA

TLDR Baricitinib is a promising treatment for severe alopecia areata with minimal side effects.

The review paper discusses the efficacy of Baricitinib, a first-generation Janus kinase (JAK) inhibitor, in treating Alopecia Areata (AA), an autoimmune condition causing patchy, non-scarring hair loss. The authors conducted a comprehensive review of research papers published from 2010-2022, focusing on the use of Baricitinib for AA treatment. The findings suggest that the use of Baricitinib for severe AA in multiple studies generally led to an improvement in patients' conditions with minimal side effects. This indicates that Baricitinib could be a promising treatment for AA.

View this study on ijord.com →

Discuss this study in the Community →

9 / 9 results

research Review of Efficacy of Baricitinib in the Treatment of Alopecia Areata

April 2023 in “International Journal of Research in Dermatology”

Baricitinib is a promising treatment for severe alopecia areata with minimal side effects.

research Case Report: Successful Treatment of Alopecia Universalis With Tofacitinib and Increased Cytokine Levels: Normal Therapeutic Reaction or Danger Signal?

June 2022 in “Frontiers in Immunology”

Tofacitinib regrew hair in a man with total hair loss but raised cytokine levels, needing more research on possible side effects.

Review of Efficacy of Baricitinib in the Treatment of Alopecia Areata

Related

research Review of Efficacy of Baricitinib in the Treatment of Alopecia Areata

research Case Report: Successful Treatment of Alopecia Universalis With Tofacitinib and Increased Cytokine Levels: Normal Therapeutic Reaction or Danger Signal?

research A Case of Atopic Dermatitis with Alopecia Universalis in a Patient Treated with Abrocitinib

research Acne Exacerbation After Tofacitinib Treatment for Alopecia Areata

research Selective Inhibition of JAK3 Signaling Is Sufficient to Reverse Alopecia Areata

research Selectively Targeting JAK1 or JAK3 Pathway Is Sufficient to Reverse Alopecia Areata

research Successful Treatment of Severe Alopecia Areata With Oral or Topical Tofacitinib

research Role of Janus Kinase Inhibitors in the Treatment of Alopecia Areata

research JAK Inhibitors in Dermatology: The Promise of a New Drug Class